Dermatomyositis Revealing Bladder Cancer Recurrence - European Medical Journal

Dermatomyositis Revealing Bladder Cancer Recurrence

*Ilyass Anouar,1 Naoufal Hjira,1 Khalid Lmezguidi2

The authors have declared no conflicts of interest.

EMJ Dermatol. ;7[1]:63-65. Abstract No AR03.
Bladder, dermatomyositis, paraneoplastic

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

There is a well-recognised association between inflammatory dermatomyopathy, dermatomyositis, and underlying visceral malignancy in adults. It is most commonly associated with malignancies arising in the lungs, breasts, and stomach. This is a report of a case found in association with transitional cell carcinoma of the bladder, a site which has only featured in a handful of previous reports.1-8

A 68-year-old man, with several weeks history of frequent micturition and haematuria under urological investigation, presented with a history of 3-months’ general illness with muscular pain and weakness, causing him difficulty arising and walking up or down stairs. Physical examination revealed photo-distributed poikiloderma with flagellate erythema of the posterior trunk and nailfold changes (includes ragged cuticles,   cuticular hypertrophy, nail-fold telangiectasia) associated with proximal scapular muscular deficit with deltoid amyotrophy (Figure 1). Routine laboratory analysis revealed that creatine phosphokinase levels had reached 1,430 UI/L (normal; 24–195 UI/L), serum lactate dehydrogenase levels were at 544 UI/L, and aldolase A reached 32 UI/L.

Figure 1: Erythematous bands on the back of hands with Gottron’s papules. Upon dermoscopy (lower-right), surface scales and dotted vessels on a homogenous pink background can be seen.

Immunological tests such as the antinuclear antibody test (titer: 320 with speckled nuclear fluorescence), and the anti-TIF1-γ antibody test, were both positive. Electromyography showed increased insertional activity and spontaneous fibrillations with abnormal myopathic low-amplitude, short-duration polyphasic motor unit potential, and complex repetitive discharges in both deltoid muscles. Transurethral cystoscopic examination of the bladder additionally revealed   a solid tumour on the left lateral wall of the   bladder, which was resected. Histological examination of this lesion revealed poorly differentiated malignant cells, with various transitional cell differentiation, indicative of a primary urothelial bladder neoplasm, without invasion of the muscle in the specimen. The paraneoplastic dermatomyositis association with bladder cancer was retained and the patient was started on intravenous methylprednisolone   bolus for 3 consecutive days with relay by oral prednisone 1 mg/kg daily. The patient showed both clinical and biological improvement, including decreased muscular enzyme levels, and surgery was planned 1 week later. However, a month after admission the patient succumbed to urinary infection with gram-negative septic shock and massive bladder bleeding.

Dermatomyositis is an acquired inflammatory dermatomyopathy.1,2 It is characterised by erythematous and oedematous changes in the skin and is associated with muscle weakness and inflammation. The muscular symptoms usually predate the skin lesions and include aching and weakness, particularly in the proximal muscle groups. Patients therefore often experience difficulty in standing up from a chair, walking up stairs, and raising their arms up above their head. The skin lesions include the characteristic purple-red heliotrope rash over the eyelids, upper cheeks, forehead, and temples. There are also small, red, flat papules, known as Gottron’s papules, and small plaques over the knuckles. Other symptoms include general malaise, fever, and, occasionally, nasal speech and regurgitation.3-5 Management of malignancy-associated dermatomyositis involves steroids, or azathioprine as an alternative, steroid-sparing agent.6 The activity of the dermatomyositis can be reflected in the state of underlying malignancy.7 Effective antitumour treatment may be accompanied by regression of the inflammation, or conversely, it may deteriorate with progressive malignant disease.8

Winter L, “Paraneoplastic syndromes in patients with malignancies of the genitourinary tract,” Sacco E, Bientinesi, R (eds.), Paraneoplastic Syndromes: Symptoms, Diagnosis and Treatment (2014), New York: Nova Science Publisher, pp.107-48. Barnes BE, Mawr B. Dermatomyositis and malignancy: A review of literature. Ann Intern Med. 1976;84(1):68-76. Robinson AJ, Alcock CJ. Dermatomyositis in association with transitional cell carcinoma of the bladder. Clin Oncol. 2001;13(1):50-1. Fitzpatrick J et al. Recurrent dermatomyositis manifesting as a sign of recurrent transitional cell carcinoma of urinary bladder: Long-term survival. Urol Ann. 2014;6(3):264-6. Siguregeirsson B et al. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med. 1992;326(6):363-7. Callen JP. Dermatomyositis. Lancet. 2000;355(9197):53-7. Sagi L et al. Dermatomyositis and small cell carcinoma of the bladder. Can Fam Physician. 2009;55(10):997-9. Almog Y et al. Dermatomyositis associated with the recurrence of transitional cell carcinomas and Kaposi’s sarcoma. Clin Exp Rheumatol. 1991;9(3):285-8.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?